trialr 0.1.4 Unreleased

Updated dependencies to account for recent breaking changes in tibble v3.0.0.

trialr 0.1.3 2020-01-08

Adjusted uses of tidyr::unnest to suppress warnings when using v1.0 of tidyr.

trialr 0.1.2 2019-06-25

Added the AugBin model for phase II response assessment in cancer. Just the two-stage single-arm version added for now. The others will follow. Also added a general routine for running simulation studies.

trialr 0.1.1 2019-05-24

Plumbed in support for tidybayes. Added pathways analysis for CRM and rewrote the same for EffTox.

trialr 0.1.0 2019-04-21

Added TITE-CRM implmentation plus tests and vignette. Rebased package to the format now advocated by rstantools.

trialr 0.0.7 2019-03-03

Making package work with staged installation, with help from Tomas Kalibera.

trialr 0.0.6 2019-01-17

Fixing some duplicated vignette titles

trialr 0.0.5 2018-11-12

Adding changes advised by rstan maintainer so that package may build on Solaris.

trialr 0.0.4 2018-10-24

Updated to use rstan 2.18.1, which in-turn has been updated to use C++14.

trialr 0.0.3 2018-08-09

This release updates some Stan code that was generating C++ code that would compile on Linux, Mac & Windows, but not Solaris.

trialr 0.0.2 2018-08-08

This release adds the Continual Reassessment Method (CRM) for dose-finding. Four model variants are currently given:

  • empiric likelihood with normal prior on slope;
  • logistic likelihood with constant intercept and normal prior on slope;
  • logistic likelihood with constant intercept and gamma prior on slope;
  • logistic likelihood with normal priors on the intercept and slope.

This release also adds general model-fitting functions stan_crm and stan_efftox. It also adds S3 classes crm_fit and efftox_fit with the expected generic methods.

Unit tests have been added.

trialr 0.0.1 2017-11-21

First release with implementations of:

  • Thall & Cook’s EffTox dose-finding clinical trial design;
  • Thall et al.’s hierarchical Bayesian phase II design for diseases with multiple subtypes
  • Brock et al.’s BEBOP design for efficacy and toxicity outcomes in phase II where predictive information